Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Bisantrene
DRUG
2 trials
Sponsors
Sheba Medical Center
Conditions
Acute Myelogenous Leukemia
Allogeneic Stem Cell Transplantation
Myelogenous Leukemia, Acute
Phase 2
Bisantrene for Relapsed /Refractory AML
Completed
NCT03820908
Sheba Medical Center
Acute Myelogenous Leukemia, Allogeneic Stem Cell Transplantation
Start: 2019-07-18
End: 2020-07-22
Updated: 2020-08-07
Bisantrene Combination for Resistant AML
NCT04989335
Sheba Medical Center
Myelogenous Leukemia, Acute
Start: 2021-08-02
End: 2025-12-01
Target: 29
Updated: 2023-11-28
Related Papers
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (<scp>AML</scp>)—An open‐label, phase I/<scp>II</scp> study
British Journal of Haematology
2025-08-01
Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study
Blood
2023-11-02
A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia
European Journal Of Haematology
2020-11-07
12 citations
A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Blood
2020-11-04
1 citations